SEEBRI Drug Patent Profile
✉ Email this page to a colleague
When do Seebri patents expire, and when can generic versions of Seebri launch?
Seebri is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has ninety-nine patent family members in thirty-two countries.
The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Seebri
A generic version of SEEBRI was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SEEBRI?
- What are the global sales for SEEBRI?
- What is Average Wholesale Price for SEEBRI?
Summary for SEEBRI
International Patents: | 99 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 113 |
Clinical Trials: | 3 |
Patent Applications: | 3,885 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SEEBRI |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SEEBRI |
DailyMed Link: | SEEBRI at DailyMed |
![SEEBRI drug patent expirations Drug patent expirations by year for SEEBRI](/p/graph/s/t/SEEBRI-patent-expirations.png)
![Drug Prices for SEEBRI](/p/graph/drug-price/SEEBRI.png)
Recent Clinical Trials for SEEBRI
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Saskatchewan | Phase 4 |
Sunovion Respiratory Development Inc. | Phase 1 |
US Patents and Regulatory Information for SEEBRI
SEEBRI is protected by two US patents.
Patents protecting SEEBRI
Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Inhaler device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SEEBRI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SEEBRI
See the table below for patents covering SEEBRI around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Brazil | 0110139 | ⤷ Sign Up | |
Japan | 2007536962 | ⤷ Sign Up | |
Norway | 973502 | ⤷ Sign Up | |
South Africa | 200208066 | Formulations for use in inhaler devices. | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 0243693 | ⤷ Sign Up | |
Slovenia | 1747036 | ⤷ Sign Up | |
United Kingdom | 0124009 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SEEBRI
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1267866 | CA 2013 00015 | Denmark | ⤷ Sign Up | |
1267866 | CR 2013 00015 | Denmark | ⤷ Sign Up | PRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, HERUNDER GLYCOPYRRONIUMBROMID; REG. NO/DATE: EU/1/12/788/001-006 20121003 |
1267866 | 16/2013 | Austria | ⤷ Sign Up | PRODUCT NAME: GLYCOPYRRONIUM, GLYCOPYRRONIUMSALZ; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928 |
1267866 | C01267866/01 | Switzerland | ⤷ Sign Up | FORMER OWNER: SOSEI R&D LTD., GB |
1267866 | CA 2014 00020 | Denmark | ⤷ Sign Up | PRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, ISAER BROMIDSALTET, I KOMBINATION MED INDACATEROL ELLER ET SALT DERAF, ISAER MALEATSALTET; REG. NO/DATE: EU/1/13/862 20130919 |
1267866 | SPC/GB13/020 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: GLYCOPYRRONIUM OR A SALT THEREOF; REGISTERED: UK EU/1/12/788/001 20120928; UK EU/1/12/788/002 20120928; UK EU/1/12/788/003 20120928; UK EU/1/12/788/004 20120928; UK EU/1/12/788/005 20120928; UK EU/1/12/788/006 20120928 |
2435024 | 2021C/518 | Belgium | ⤷ Sign Up | PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |